|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-8-26
|
|
pubmed:abstractText |
Control of inflammation using appropriate anti-inflammatory agent prevents wound from becoming chronic. Heparin is a heterogeneous mixture of polysaccharide molecules with a mean molecular weight between 12-30 kDa containing 200-300 disaccharide units of glycosaminoglycan chains. Chemical modifications leading to generation of a unique pentasaccharide sequence effectively reduces its anticoagualant activity, while retaining its anti-inflammmatory property. In this study, Standard heparin was partially desulfated to 2, 3 desulfated heparin (2, 3 DSH) and its anti-inflammatory property was determined by assessing its ability to prevent static adhesion of leukocytes to endothelium and clotting assay. The effectiveness of 2, 3 DSH to down regulate E-selectin and key proinflammatory cytokines (IL-1beta and IL-6) was assessed by western blot and immunocytochemistry. These results were compared with commercially available 2-Desulfated Heparin (2DSH) and standard heparin (SH). Finally, a controlled delivery system of 2, 3 DSH was designed using chitosan microspheres and collagen as scaffold. Optimal loading of 2, 3 DSH was achieved and the release kinetics were tuned to follow a controlled release pattern. The steady state concentration of 2, 3 DSH was found to be optimal to elicit anti-inflammatory property and could achieve inhibition of E-selectin expression while unaffecting the normal clotting cascade.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1552-4965
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2010.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
118-28
|
|
pubmed:meshHeading |
pubmed-meshheading:20540094-Anti-Inflammatory Agents,
pubmed-meshheading:20540094-Biological Assay,
pubmed-meshheading:20540094-Blood Coagulation,
pubmed-meshheading:20540094-Blotting, Western,
pubmed-meshheading:20540094-Carbohydrate Conformation,
pubmed-meshheading:20540094-Chitosan,
pubmed-meshheading:20540094-Collagen,
pubmed-meshheading:20540094-Cytokines,
pubmed-meshheading:20540094-Delayed-Action Preparations,
pubmed-meshheading:20540094-E-Selectin,
pubmed-meshheading:20540094-Endothelial Cells,
pubmed-meshheading:20540094-Fluoresceins,
pubmed-meshheading:20540094-Heparin,
pubmed-meshheading:20540094-Humans,
pubmed-meshheading:20540094-Inflammation Mediators,
pubmed-meshheading:20540094-Magnetic Resonance Spectroscopy,
pubmed-meshheading:20540094-Microscopy, Electron, Scanning,
pubmed-meshheading:20540094-Microspheres,
pubmed-meshheading:20540094-Molecular Weight,
pubmed-meshheading:20540094-Partial Thromboplastin Time,
pubmed-meshheading:20540094-Reproducibility of Results,
pubmed-meshheading:20540094-Tissue Scaffolds
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Controlled release of 2, 3 desulfated heparin exerts its anti-inflammatory activity by effectively inhibiting E-selectin.
|
|
pubmed:affiliation |
Biomaterials Division, Central Leather Research Institute, Chennai, Tamil Nadu, India.
|
|
pubmed:publicationType |
Journal Article
|
